[DISCLOSURE] Macrogen (038290), a genome sequencing firm, announced on Sept. 21 that it has gained a patent for extracting fusion protein that encodes RET fusion protein which can be used as a diagnostic marker of cancer.
The patent includes primer pair of base sequence to detect KIF5B fusion protein and composite to inhibit activation of relevant fusion protein of lung cancer.
